Table 2 Resistance data.

From: Complete-genome sequencing elucidates outbreak dynamics of CA-MRSA USA300 (ST8-spa t008) in an academic hospital of Paramaribo, Republic of Suriname

Antibiotic

ATCC29213 (MIC a )

USA 300 isolates from Suriname (MIC a )

Acquired gene(s)

Location

Core gene

Substitution

Penicillin

R (0.5)

R (24–48)

blaZ

pUSA04

  

Oxacillin

S (0.25)

R (>256)

mecA

SCCmec cassette

  

Cefoxitin

S (3)

R (24–128)

mecA

SCCmec cassette

  

Vancomycin

S (0.75)

S (0.50–1)

    

Clindamycin

S (0.047)

S (0.047–0.094) and R (>256) b

ermC

pUSA05

  

Linezolid

S (2)

S (0.75–3)

    

Rifampicin

S (0.008)

S (0.004–0.012) and R (>32) c

  

rpoB

H481Y

Sulfamethoxazole/Trimethoprim

S (0.032)

S (0.0320.75)

    

Gentamicin

S (0.38)

S (0.19–0.75)

    

Kanamycin

S (3)

R (>256)

aphA3

pUSA04

  

Streptomycin

S (6)

S (3–12) and R (>1024) c

str

pUSA06

  

Tobramycin

S (0.25)

S (0.25–1)

    

Ciprofloxacin

S (0.25)

R (>32)

  

grlA

S80Y

gyrA

S84L

Erythromycin

S (0.5)

R (32- > 256)

msrA, mphC

pUSA04

  

Mupirocin

S (0.094)

S (0.094–0.25)

    

Minocycline

S (0.094)

S (0.047–0.125)

    

Tetracycline

S (0.75)

S (0.125–1)

    

Bacitracin

R (>256)

R (>256)

bcrA, bcrB

pUSA04

  

Chloramphenicol

S (4)

S (3–8)

    

Daptomycin

S (0.25)

S (0.125–0.75)

    

Fusidic Acid

S (0.125)

S (0.032–0.5)

    
  1. aμg/ml.
  2. bResistance only in two isolates (SUR15 and SUR24) of cluster A.
  3. cResistance only in cluster.